345TiP: A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homologue 3 (B7-H3) protein-targeted antibody-drug conjugate (ADC), in combination with standard of care (SoC), in patients with advanced solid tumours, including lung cancers | Publicación